Cargando…
p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo
p53 is an important modulator of stem cell fate, but its role in cardiac progenitor cells (CPCs) is unknown. Here, we tested the effects of a single extra-copy of p53 on the function of CPCs in the presence of oxidative stress mediated by doxorubicin in vitro and type-1 diabetes in vivo. CPCs were o...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474510/ https://www.ncbi.nlm.nih.gov/pubmed/28163043 http://dx.doi.org/10.1016/j.ebiom.2017.01.028 |
_version_ | 1783244460372525056 |
---|---|
author | Kannappan, Ramaswamy Matsuda, Alex Ferreira-Martins, João Zhang, Eric Palano, Giorgia Czarna, Anna Cabral-Da-Silva, Mauricio Castro Bastos-Carvalho, Adriana Sanada, Fumihiro Ide, Noriko Rota, Marcello Blasco, Maria A. Serrano, Manuel Anversa, Piero Leri, Annarosa |
author_facet | Kannappan, Ramaswamy Matsuda, Alex Ferreira-Martins, João Zhang, Eric Palano, Giorgia Czarna, Anna Cabral-Da-Silva, Mauricio Castro Bastos-Carvalho, Adriana Sanada, Fumihiro Ide, Noriko Rota, Marcello Blasco, Maria A. Serrano, Manuel Anversa, Piero Leri, Annarosa |
author_sort | Kannappan, Ramaswamy |
collection | PubMed |
description | p53 is an important modulator of stem cell fate, but its role in cardiac progenitor cells (CPCs) is unknown. Here, we tested the effects of a single extra-copy of p53 on the function of CPCs in the presence of oxidative stress mediated by doxorubicin in vitro and type-1 diabetes in vivo. CPCs were obtained from super-p53 transgenic mice (p53-tg), in which the additional allele is regulated in a manner similar to the endogenous protein. Old CPCs with increased p53 dosage showed a superior ability to sustain oxidative stress, repair DNA damage and restore cell division. With doxorubicin, a larger fraction of CPCs carrying an extra-copy of the p53 allele recruited γH2A.X reestablishing DNA integrity. Enhanced p53 expression resulted in a superior tolerance to oxidative stress in vivo by providing CPCs with defense mechanisms necessary to survive in the milieu of the diabetic heart; they engrafted in regions of tissue injury and in three days acquired the cardiomyocyte phenotype. The biological advantage provided by the increased dosage of p53 in CPCs suggests that this genetic strategy may be translated to humans to increase cellular engraftment and growth, critical determinants of successful cell therapy for the failing heart. |
format | Online Article Text |
id | pubmed-5474510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-54745102017-06-26 p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo Kannappan, Ramaswamy Matsuda, Alex Ferreira-Martins, João Zhang, Eric Palano, Giorgia Czarna, Anna Cabral-Da-Silva, Mauricio Castro Bastos-Carvalho, Adriana Sanada, Fumihiro Ide, Noriko Rota, Marcello Blasco, Maria A. Serrano, Manuel Anversa, Piero Leri, Annarosa EBioMedicine Research Paper p53 is an important modulator of stem cell fate, but its role in cardiac progenitor cells (CPCs) is unknown. Here, we tested the effects of a single extra-copy of p53 on the function of CPCs in the presence of oxidative stress mediated by doxorubicin in vitro and type-1 diabetes in vivo. CPCs were obtained from super-p53 transgenic mice (p53-tg), in which the additional allele is regulated in a manner similar to the endogenous protein. Old CPCs with increased p53 dosage showed a superior ability to sustain oxidative stress, repair DNA damage and restore cell division. With doxorubicin, a larger fraction of CPCs carrying an extra-copy of the p53 allele recruited γH2A.X reestablishing DNA integrity. Enhanced p53 expression resulted in a superior tolerance to oxidative stress in vivo by providing CPCs with defense mechanisms necessary to survive in the milieu of the diabetic heart; they engrafted in regions of tissue injury and in three days acquired the cardiomyocyte phenotype. The biological advantage provided by the increased dosage of p53 in CPCs suggests that this genetic strategy may be translated to humans to increase cellular engraftment and growth, critical determinants of successful cell therapy for the failing heart. Elsevier 2017-01-31 /pmc/articles/PMC5474510/ /pubmed/28163043 http://dx.doi.org/10.1016/j.ebiom.2017.01.028 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research Paper Kannappan, Ramaswamy Matsuda, Alex Ferreira-Martins, João Zhang, Eric Palano, Giorgia Czarna, Anna Cabral-Da-Silva, Mauricio Castro Bastos-Carvalho, Adriana Sanada, Fumihiro Ide, Noriko Rota, Marcello Blasco, Maria A. Serrano, Manuel Anversa, Piero Leri, Annarosa p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo |
title | p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo |
title_full | p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo |
title_fullStr | p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo |
title_full_unstemmed | p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo |
title_short | p53 Modulates the Fate of Cardiac Progenitor Cells Ex Vivo and in the Diabetic Heart In Vivo |
title_sort | p53 modulates the fate of cardiac progenitor cells ex vivo and in the diabetic heart in vivo |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474510/ https://www.ncbi.nlm.nih.gov/pubmed/28163043 http://dx.doi.org/10.1016/j.ebiom.2017.01.028 |
work_keys_str_mv | AT kannappanramaswamy p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT matsudaalex p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT ferreiramartinsjoao p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT zhangeric p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT palanogiorgia p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT czarnaanna p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT cabraldasilvamauriciocastro p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT bastoscarvalhoadriana p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT sanadafumihiro p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT idenoriko p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT rotamarcello p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT blascomariaa p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT serranomanuel p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT anversapiero p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo AT leriannarosa p53modulatesthefateofcardiacprogenitorcellsexvivoandinthediabeticheartinvivo |